Ebrahimloee, Saba
Masoumpoor, Anahita
Nasiri, Malihe
Babaie, Mohadese
Farahani, Amirparsa Vanaki
Yousefiasl, Sepideh
Farahani, Azam Shirinabadi
Article History
Received: 26 January 2022
Accepted: 21 December 2022
First Online: 29 December 2022
Declarations
:
: This study was approved by the ethics committee of Shahid Beheshti university of Medical Sciences, Tehran, Iran under the ethics code IR.SBMU.PHARMACY.REF.1398.054, and registered under the code IRCT20190906044710N1 in Iranian Registry of Clinical Trials, on 16/09/2019. All methods were performed in accordance with declaration of Helsinki. Participants and their parents were provided with information about the study aim and the confidential management of their data and then, their written informed consents were obtained.
: Not applicable. The results should be interpreted with caution because this experiment was conducted in a controlled environment.
: The authors declare that they have no competing interests.